🟢 GRAIL is trading 5.85% up today after FDA panel backed Galleri’s benefit-risk profile

GRAIL is trading 5.85% up at $114.87 after an FDA advisory panel supported Galleri’s benefit-risk profile for approval on September 23, 2026.

• The panel voted 7–2 in favor, with one abstention; support for effectiveness was narrower at 6–4.
• The recommendation is nonbinding, and efficacy concerns remain.
• Biotech weakness and broader market losses provided a modest counterweight, while the FDA development was the clearest catalyst.